Clinical Study, Multicenter, Randomized With 2 Arms of Pantoprazole + Domperidone and Pantoprazole Isolated at the Gastroesophageal Reflux Disease (PANDA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Rio de Janeiro, Brazil
- Rio de Janeiro
-
-
Goias
-
Goiania, Goias, Brazil
- Goiania
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil
- Belo Horizonte
-
-
Paraná
-
Curitiba, Paraná, Brazil
- Curitiba
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil
- Porto Alegre
-
-
São Paulo
-
Campinas, São Paulo, Brazil
- Campinas
-
Jaú, São Paulo, Brazil
- Jaú
-
São José do Rio Preto, São Paulo, Brazil
- São José Do Rio Preto
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subscription of IC;
- Age ≥ 18 years and <70 years
- Diagnosis initial clinical or previous symptomatic GERD;
- Symptom score ≥ 4;
- Ability to conduct examinations of endoscopy;
- Ability to perform washout of drug classes PPIs, H2 antagonists, and prokinetics for at least 14 days.
Exclusion Criteria:
- Presence of esophagitis requiring intervention, esophageal varices, Barrett's esophagus, scleroderma, ulcers (gastric or duodenal), atrophic gastritis, or vagotomy pangastritis detected at the time of study enrollment;
- Eradication treatment of H. pylori completed less than 15 days of V0;
- Presence of alarm symptoms (weight loss greater than 5% in the last 60 days, no evidence of gastrointestinal bleeding);
- Gastric or esophageal surgery prior (except for simple ulcer closure);
- Females in pregnancy, lactation, or who wish to become pregnant if they refuse to use adequate contraception during the study period.
- Concomitant serious diseases such as kidney failure, heart and liver;
- Suspected or confirmed any cancer except carcinoma in situ or nonmelanoma skin cancer diagnosed in the last 5 years;
- History of gastric cancer in relatives of 1st degree;
- Use of illicit drugs or alcohol abuse according to the investigator;
- Values changed (outside the normal range for the local laboratory) in leukocytes, platelets or hemoglobin;
- Significant changes in serum sodium, potassium, calcium or creatinine;
- Intolerance or allergy to any component of the drugs evaluated in the study;
- Use of anti-inflammatory drugs (NSAIDs), antiemetics, macrolides and systemic steroids for a period of not less than 2 weeks prior to the study or who have expected necessity of prolonged use during the study treatment;
- Current use of bisphosphonates, as well as those who need calcium channel blockers or other drugs that affect esophageal motility or lower esophageal sphincter tone.
- Use of other scheduled medications metabolized by cytochrome CYP3A4 during the study;
- Participation recent (past 12 months) or participation in a clinical trial expected during this study in other clinical trials involving drugs of any kind.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pantoprazole + Domperidone
The combination of pantoprazole and domperidone provided for the study will be the new incremental formulation produced by Eurofarma.
For this study will be used doses of capsules containing 20 mg pantoprazole, 20 mg of domperidone.
|
|
|
Active Comparator: Pantozol® (Takeda)
The Pantozol® may be presented in boxes of coated tablets of 20 mg or 40 mg.
For this study will be used 20 mg tablets.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the efficacy of pantoprazole + domperidone Eurofarma at the treatment of gastroesophageal reflux disease in relation to the reference drug during 56 days using the score of symptoms
Time Frame: Evaluation at the gastroesophageal reflux disease in 56 treatment days
|
The primary objective of the study is to evaluate the efficacy of combining incremental pantoprazole and domperidone Eurofarma the treatment of gastroesophageal reflux disease in relation to the reference drug.
The primary endpoint is the score of symptoms (heartburn and regurgitation) including the severity and frequency after treatment
|
Evaluation at the gastroesophageal reflux disease in 56 treatment days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Quality of life during the study treatment
Time Frame: Evaluation at the gastroesophageal reflux disease in 56 treatment days
|
Evaluation at the gastroesophageal reflux disease in 56 treatment days
|
|
Endoscopic cure rate for patients with erosive gastroesophageal reflux disease
Time Frame: Evaluation at the gastroesophageal reflux disease in 56 treatment days
|
Evaluation at the gastroesophageal reflux disease in 56 treatment days
|
|
Frequency of adverse events observed
Time Frame: Evaluation at the gastroesophageal reflux disease in 56 treatment days
|
Evaluation at the gastroesophageal reflux disease in 56 treatment days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Gastroenteritis
- Intestinal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Esophagitis
- Peptic Ulcer
- Duodenal Diseases
- Gastroesophageal Reflux
- Esophagitis, Peptic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Antiemetics
- Gastrointestinal Agents
- Dopamine Agents
- Dopamine Antagonists
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Pantoprazole
- Domperidone
Other Study ID Numbers
Other Study ID Numbers
- EF129
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.